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Abstract: Background: Antiretroviral (ART) scale-up in Malawi has been achieved on a large scale based mainly on 
clinical criteria. Simple markers of prognosis are useful, and we investigated the value of very early anthropometric 
changes in predicting mortality. 
Methods: Principal findings: Adult patients who initiated ART in Karonga District, northern Malawi, between September 
2005 and August 2006 were included in a prospective cohort study, and followed for up to one year. We used Cox 
regression to examine the association between anthropometric changes at 2 and 6 weeks and deaths within the first year. 
573 patients were included, of whom 59% were women; the median age at initiation was 37 and 64% were in WHO stage 
4. Both body mass index (BMI) and mid-upper arm circumference (MUAC) increased linearly with increased time on 
ART, and were closely correlated with each other. There were 118 deaths. After 2 weeks on ART, a BMI increase of <0.5 
kg/m
2 (HR 2.47, 95%CI 1.24-4.94, p=0.005) or a MUAC increase of <0.5cm (HR 2.79, 95%CI 1.19-6.55, p=0.008) were 
strong predictors of death, and these associations were stronger after adjusting for baseline charactertistics. Similar results 
were found after 6 weeks on ART. 
Conclusions: Very early anthropometric changes, after 2 and 6 weeks on ART, are strong predictors of survival, 
independent of baseline characteristics. This should help identify patients requiring more detailed assessment where 
facilities are limited. MUAC is particularly valuable, requiring the simplest equipment and being appropriate for patients 
who have problems standing. 
Keywords: Anthropometric measure, antiretroviral therapy, HIV, Mortality, sub-Saharan Africa. 
INTRODUCTION 
  The HIV epidemic has affected Karonga district, Malawi 
since the early 1980s [1]. The HIV prevalence among adults 
aged 15-45 rose from 2.1% in 1990 to 11.9% in 2007[2]. In 
2004, Malawi began a rapid scale-up program, using clinical 
criteria for antiretroviral therapy (ART) eligibility and 
follow-up when CD4 cell counts were not available [3]. By 
the end of 2007, more than 100,000 patients were receiving 
treatment. ART dramatically improved the prognosis, 
however mortality within the first months of treatment   
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initiation remained high, as shown in other studies from low-
income countries [4-6]. 
  Among clinical criteria, anthropometric measurements 
play an important role in the initial assessment of the patient. 
Low Body Mass Index (BMI) at the initiation of ART has 
been shown to be a strong predictor of death [7-10]. 
However, few studies describe anthropometric changes in 
patients after initiation of ART [11]. In a study in Abidjan, 
Ivory Coast, the mean BMI increase was modified by 
baseline BMI values, and anthropometric change was a 
strong predictor of virological response [11]. Two recent 
studies found an association between anthropometric 
changes at 3 and 6 months and mortality [12, 13]. However, 
information on the relationship between earlier 
anthropometric changes and mortality is lacking. Very Early Anthropometric Changes After Antiretroviral Therapy  The Open AIDS Journal, 2012, Volume 6    37 
  First line ART in Malawi uses triple-therapy which 
includes a fixed dose of Nevirapine. With this treatment 
regimen, the patient only receives half a dose of Nevirapine 
for the first 2 weeks to reduce the risk of a hypersensitivity 
reaction. The dose is doubled after a 2-week check-up to 
make sure there are no side effects. This makes the 2-week 
consultation time critical for the assessment of the patient’s 
recovery, treatment adherence and potential side-effects. 
  Mid-upper arm circumference (MUAC) is a less common 
tool than BMI to monitor nutritional status of HIV-infected 
patients on ART. One study found MUAC at treatment 
initiation to be a predictor of death [14], but no other studies 
examining MUAC changes have been done. However 
MUAC is a potentially useful indicator, requiring only a 
cheap, widely available and durable measuring tape, that 
requires no calibration, and having the advantage that it can 
be measured in patients who have difficulty standing. 
  The aim of this analysis is to describe early 
anthropometric changes after ART initiation, and explore the 
association between absolute anthropometric changes after 2 
weeks and 6 weeks on ART with mortality. 
METHODS 
Setting 
  The Karonga Prevention Study was established in 1979 
in the rural district of Karonga in northern Malawi. A 
demographic surveillance system was initiated in 2002 and 
studies on HIV, tuberculosis and pneumococcal disease are 
ongoing. An ART clinic, known as the Buyu clinic [15], first 
opened at the Karonga district hospital on June 22, 2005, as 
a part of a government initiative to scale up ART access 
across the country [3]. The initial government target for this 
clinic was to start up to 50 patients per month on ART, in 
addition to the “transferred in” patients who had already 
initiated treatment elsewhere. 
Study Population 
  HIV positive patients who came for screening at the 
Buyu clinic between September 12, 2005 and August 31, 
2006 were asked if they would take part in a study on access, 
uptake and outcome of ART. Patients attending the clinic in 
this period were included in the study if: (a) they initiated 
ART based on a fixed dose combination of Stavudine, 
Lamivudine and Nevirapine; (b) they had not had prior ART 
treatment when they joined the clinic (apart from Nevirapine 
for prevention of mother-to-child transmission); (c) they 
agreed to participate and gave their written consent; and (d) 
they were above the age of 14 years at the time of initiation. 
Patients started treatment based on clinical criteria, if they 
were WHO stage three or four, or had a CD4 count < 250 
cells/l (if available), following Malawi Government 
guidelines. 
Outcomes and Exposures 
  Death was either reported by relatives/friends of the 
patients or was identified via a tracking team employed by 
the study. The team visited the patients’ home if they were 
more than 10 days late for a clinic appointment. 
  The height of every patient was measured during the first 
consultation. Weight and the MUAC were measured at every 
consultation. BMI is defined as weight in kilograms divided 
by the squared height in meters. The WHO defines Chronic 
Energy Deficiency (CED) in adults [16] as mild if the BMI 
lies between 17 and 18.4 kg/m
2, severe if it is between 16 
and 16.9 kg/m
2 and very severe if the BMI is below 16 
kg/m
2. The WHO define CED cut-off points for MUAC at 
22cm for women and 23cm for men [17]. The MUAC was 
measured to the nearest 0.1cm at the midpoint of the upper 
arm and always measured on the same arm. 
  BMI and MUAC changes at a particular point in time 
after ART initiation were categorized as binary variables 
representing an increase of at least 0.5kg/m
2 for the BMI, 
and of at least 0.5 cm for MUAC. These cut-off points were 
chosen to ensure a minimum number of patients (at least 
30%) in each category at any point in time. No guidance for 
different cut-offs could be found in the literature. We chose 
to use absolute changes rather than relative changes, as this 
enables the development of practical clinical 
recommendations for clinicians and others to use during 
patient follow-up. 
Statistical Analysis 
  Aggregated means and their 95% confidence intervals for 
anthropometric changes at different time points after ART 
initiation were calculated. Means and medians were close, as 
BMI and MUAC were normally distributed, so means and 
confidence intervals are presented throughout. The 
correlation between MUAC and BMI, before and after ART 
initiation was assessed using Pearson correlation 
coefficients. 
  Survival analysis was used to examine the association 
between baseline and early anthropometric changes (at 2 and 
at 6 weeks) and death. Two different measures of 
anthropometric change were considered in the analysis: 
absolute changes in BMI and MUAC, at the two time points. 
The association between baseline risk factors and death were 
estimated using univariate and multivariate Cox regression. 
Mortality hazard ratios were calculated with 95% confidence 
intervals. Likelihood ratio tests were also performed to 
determine the significance of each factor in the model. 
  For the baseline analysis, time of entry to the analysis 
was defined as the day patients initiated ART. To assess the 
effect of anthropometric changes, time of entry to the 
analysis was the day the measurement was taken at 2 weeks 
(or 6 weeks), so only the patients alive at this time point on 
ART were included in the cohort (left censoring). End of 
follow-up occurred the day the patient died, the day the 
patient was transferred out of the program or at the end of 
the study (end of August 2006). 
  The association between early anthropometric changes 
and death was examined by Cox regression, adjusted for 
baseline BMI (or MUAC), WHO stage, sex and age. We also 
looked for potential effect modification by baseline 
anthropometric characteristics by exploring interaction terms 
and testing their significance using likelihood ratio tests. 
  The association between missing weights, heights and 
MUAC with death was examined using multivariate Cox 
regression, and mortality hazard ratios were calculated at 2 
and 6 weeks after initiation of ART. Patients with missing 
values in these key variables were excluded from the 38    The Open AIDS Journal, 2012, Volume 6  Maman et al. 
analysis. Kaplan-Meier survival curves were used to 
compare survival by early anthropometric changes at 2 and 6 
weeks. The data were analyzed using Stata 10 (Stata Corp., 
College station, Texas, USA) 
Ethics Statement 
  The study was approved by the Malawi National Health 
Sciences Research Committee and the London School of 
Hygiene & Tropical Medicine, UK. 
RESULTS 
Study population 
  As outlined in Fig. (1), 573 patients met the inclusion 
criteria for the study, giving a total of 174.5 person-years at 
risk. The median duration of follow-up on ART was 2.86 
months (InterQuartile Range IQR 1.38-5.5). Baseline 
characteristics are displayed in Table 1. Among the 573 
patients eligible, 59% of the participants were women and 
the median age at initiation was 37.4 years (IQR 31.6; 44.6). 
237 patients (41%) were farmers and 165 (29%) had 
received more than 10 years of education. At initiation, 369 
patients (64%) were Stage 4 according to the WHO scale. 
Anthropometry 
  The mean BMI and MUAC at baseline were 18.6 kg/m
2 
(95% CI 18.4 to 18.8) and 22.8cm (95%CI 22.6 to 23.1) 
respectively. The mean changes of BMI and MUAC initially 
followed a linear trend with time on ART (Fig. 2). The mean 
increase in BMI was 0.15 kg/m
2 (446 observations, 95%CI 
0.07 to 0.22) at 2 weeks, 0.45 kg/m (346 observations, 
95%CI 0.33 to 0.58) at 6 weeks and 1.58 kg/m
2 (111 
observations, 95%CI 1.25 to 1.92) at 6 months after ART 
initiation (Fig. 2). The mean MUAC change was -0.06cm 
(444 observations, 95%CI -0.29 to 0.01) after 2 weeks on 
ART, 0.12cm (346 observations, 95%CI -0.04 to 0.29) at 6 
weeks and 1.24cm at 6 months (111 observations, 95%CI 
0.87 to 1.62). Using all measurements taken across time 
points (giving 2492 observations), the Pearson correlation 
coefficient was 0.86 between the values of BMI and MUAC, 
suggesting a strong correlation between the two indicators. 
Survival Analysis 
  During follow-up, 118 patients died. Among them, 26, 46 
and 45 deaths happened during the first 2 weeks, between 2 
and 6 weeks and between 6 weeks and 6 months after ART  
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Table 1.  Patient Characteristics at ART Initiation 
 
Characteristics  Overall (%) (Total 573) 
Sex   
Female  338 (59) 
Male  235 (41) 
Age (years)   
<25  40 (7) 
25 and 35  206 (36) 
35 and 45  193 (34) 
> 45  134 (23) 
Education (in Years of School) (Missing 5) 
0  29 (5) 
Between 1 and 4  75 (13) 
Between 5 and 9  299 (29) 
10 or more  165 (29) 
Occupation 
(Missing : 4) 
 
Farmer  237 (41) 
Other  194 (34) 
No occupation  138 (24) 
Marital Status   
Divorced  117 (20) 
Married  276 (48) 
Single  21 (4) 
Widowed  159 (28) 
WHO Stage   
Stage2  6 (1) 
Stage 3  198 (35) 
Stage 4  369 (64) 
Body Mass Index (Kg/m
2) (Missing: 4) 
>= 18,5   297 (52) 
Between 17 and 18,5  109(19) 
Between 16 and 17  72 (13) 
<16  91 (16) 
MUAC   
No CED*  320 (56) 
CED  253 (44) 
CED: Chronic Energy Deficiency. 
 
initiation, respectively. Kaplan Meier estimates for survival 
were 0.95 (95%CI 0.93 to 0.97) at 2 weeks, 0.87 (95%CI 
0.83 to 0.89) after 6 weeks and 0.75 (95%CI 0.70 to 0.79) 
after 6 months on ART. 
Association Between Baseline Characteristics and Death 
  In a univariate analysis, men, and those with initial WHO 
stage 4, lower baseline BMI, and lower baseline MUAC, had 
higher mortality rates. In the multivariate analysis, except 
gender, these variables remained associated with death after 
adjustment (Table 2). 
Missing Values 
  Among the 517 patients who came to the clinic for their 
visit 2 weeks after ART initiation, 74 had missing BMI and 
70 missing MUAC values (70 patients were missing both). 
The patients with missing measurements had a higher rate of 
death compared to those who had these measurements: for 
BMI, HR 2.57; 95%CI 1.57 to 4.22, Likelihood ratio test 
(LRT) p<0.001; for MUAC, HR 2.57; 95%CI 1.57 to 4.22; 
LRT p<0.001. The association was similar for patients who 
had missing values at 6 weeks on ART for BMI (59 missing, 
HR 2.32; 95%CI 0.90; 6.01; LRT p=0.08) and MUAC (58 
missing, HR 2.40; 95%CI 0.92; 6.28; LRT p=0.07) (Table 
3). 
Association Between Early Anthropometric Changes and 
Death 
  After 2 weeks on ART, a BMI increase of less than 0.5 
kg/m
2  was strongly associated with higher subsequent 
mortality (Table 4). The association was stronger after 
adjusting for sex, age, baseline categories of BMI, and WHO 
initial stage, (HR 2.47, 95%CI 1.24 to 4.93, p=0.005). The 
effect was similar by different baseline categories of BMI 
(LRT for interaction p= 0.69). Similar results were found 
when a 2-week MUAC increase of less than 0.5cm was 
considered (HR 2.78 95%CI 1.19 to 6.53 p=0.008). 
  After 6 weeks on ART, a BMI increase of less than 0.5kg/m
2 
was associated with a 3 times higher mortality on univariate and 
multivariate analysis (HR 3.41 95%CI 1.24 to 9.39 LRT 
p=0.01). MUAC change of less than 0.5cm at 6 weeks was also 
associated with increased mortality (HR 2.34 95%CI 0.85 to 
6.39, LRT p=0.078), albeit not statistically significant. 
  The combined effect of baseline and 2-week changes of 
anthropometric measures on mortality over time are presented 
in Figs. (3, 4). For those with a baseline BMI < 18.5 kg/m, 
failure to recover at least 0.5kg/m after 2 weeks on ART was 
associated with much worse survival: the Kaplan Meier 
estimate for survival at 3 months was 0.73 (95% CI 0.63 to 
0.81), compared to 0.85 (95% CI 0.72 to 0.92) in those who had 
gained at least 0.5kg/m
2. For those with a baseline BMI of at 
least 18.5 kg/m failure to increase their BMI by at least 0.5 
kg/m after 2 weeks under treatment was also associated with 
worse survival (Fig. 3), compared to very few deaths in those 
who increased their BMI (3 month survival estimate 0.99 (95% 
CI 0.90 to 1)). Similar trends are found when baseline MUAC 
and 2-week changes are considered (Fig. 4). Those with CED at 
baseline who failed to recover 0.5 cm of MUAC after 2 weeks 
of ART experienced worse survival than who had gained at 
least 0.5cm, with a Kaplan Meier estimate for survival at 3 
months of 0.74 (95%CI 0.64 to 0.82) and 0.93 (95%CI 0.88 to 
0.96) respectively. For those with no CED at time of ART start, 
the estimate survival at 3 months was 0.98 (95%CI 0.89 to 1) 
for those who recovered at least 0.5cm of MUAC after 2 weeks 
of ART. 
DISCUSSION 
  Anthropometric changes at 2 and 6 weeks are strong 
predictors of survival after initiation of ART, independent of 
baseline measurements. Baseline anthropometric status did 
not modify the association between these changes and 40    The Open AIDS Journal, 2012, Volume 6  Maman et al. 
mortality. Although two previous studies have provided 
evidence of the prognostic values of anthropometric changes 
after 3 and 6 months on ART [12, 13], none has examined 
this association for earlier anthropometric changes, when the 
mortality rate is generally higher. 
  These findings can help identify patients at risk, allowing 
further investigation of, for example: whether patients have 
an adherence problem, the deterioration of tuberculosis or 
another opportunistic infection, a hypersensitivity reaction or 
an Immune Reconstitution Inflammatory Syndrome. The use 
of simple cut-off points could be particularly useful in 
remote areas to detect patients at higher risk of death, and in 
settings where only clinical follow-up is feasible, and care is 
usually provided by nurses and other non-physicians facing a 
high workload. Early anthropometric changes can also be 
useful to detect patients who are at very low risk of death, in 
order to use human resources more efficiently, a major 
concern in these settings. Combining the effects of baseline 
and 2-week changes of anthropometric measures on ART 
could be of clinical importance, by, for example, creating a 
different consultation schedule based on these two 
predictors. 
  MUAC appears to be a valuable alternative to BMI for 
follow-up of anthropometric changes. They are closely 
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correlated and MUAC is simple and can be an easier tool 
especially for patients who cannot stand, or get their weight 
or height checked easily, although training is required to 
ensure that the MUAC is measured accurately. It could also 
be used for home-based care, as the measuring tapes are easy 
to carry. However, there will be times when it is not 
appropriate, for example, a patient might have an oedema of 
the arm where the MUAC is usually measured (e.g., due to 
Kaposi sarcoma). 
  Two weeks after initiation of treatment a significant 
increase in BMI was noted, highlighting the rapid effect of 
treatment and the associated programme of care on patients’ 
recovery. Although the mean MUAC of the patients did not 
increase at 2 weeks, unlike BMI, changes in MUAC and 
Table 2.  Baseline Characteristics of the Population and Association with Death, Univariate and Multivariate Analysis, Cox Model 
 
Characteristics  Overall (%) 
(Total 573) 
Deaths  
(Total 118) 
Y  
(Person-Year) 
Univariate HR‡ 
(95% CI) 
P Value*  Multivariate HR‡‡  
(95% CI) 
P Value* 
Sex          p=0.021    P=0.12 
Female  338 (59)  58  104.3  1   1   
Male  235 (41)  60  70.3  1.53 (1.07; 2.19)    1.36 (0.93; 2.00)   
Age (years)         p=0.71    P=0.07 
<25  40 (7)  7  13.5  1    1   
25 and 35  206 (36)  38  59.7  1.13 (0.50; 2.13)    1.28 (0.57; 2.87)   
35 and 45  193 (34)  42  60.4  1.34 (0.60; 2.98)    1.89 (0.83; 4.27)   
> 45  134 (23)  31  41.0  1.40 (0.62; 3.18)    1.74 (0.76; 4.02)   
WHO Stage          p<0.001    P=0.008 
Stage 2**  6 (1)            
Stage 3  198 (35)  22  59.0  1    1   
Stage 4  369 (64)  96  113.6  2.42 (1.53; 3.86)    1.85 (1.14; 2.99)   
Body Mass Index (Kg/m
2) (Missing: 4)     
p<0.001 
 
  p<0.001 
(ptrend<0.001) 
 18.5   297 (52)  30  100.7  1    1   
17-18.4  109(19)  21  34.9  2.13 (1.21; 3.72)    1.39 (0.75; 2.59)   
16-16.9  72 (13)  19  20.52  3.01 (1.69; 5.35)    1.58 (0.78; 3.22)   
<16  91 (16)  45  18.1  6.86 (4.32; 10.9)    3.66 (1.90; 7.05)   
MUAC         p<0.001    P=0.09 
No CED  320 (56)  31  112.4  1    1   
CED  253 (44)  87  62.1  4.48 (2.97; 6.76)    2.19 (1.21; 3.96)   
*likelihood ratio test. 
** Stage 2 and 3 pooled in the analysis. 
‡ Hazard Ratio. 
‡‡Multivariate HR adjusted for all other factors in the table. 
 
Table 3.  Association Between Missing Anthropometric Measures and Death Among Patients who Came at their Consultation, 
Multivariate Cox Regression 
 
  Missing Values  Non Missing Values  Hazard-Ratio* (95%CI)  p-Value** 
  N  Deaths  PY  N  Deaths  PY     
Weight                
At 2 weeks  71  27  18.3  446  54  150.6  2.57 (1.57; 4.22)  p<0.001 
At 6 weeks  59  6  38.7  346  22  239.6  2.32 (0.90; 6.01)  p=0.082 
MUAC                 
At 2 weeks  70  27  18.6  447  54  150.3  2.57 (1.57; 4.22)  p<0.001 
At 6 weeks  58  6  19.7  347  22  139.0  2.40 (0.92; 6.28)  p=0.072 
*Adjusted by baseline BMI, WHO stage, age and gender. 
**Wald test. 42    The Open AIDS Journal, 2012, Volume 6  Maman et al. 
BMI at 2 weeks were similarly predictive of subsequent 
survival. The median MUAC and BMI increase follow a 
linear trend throughout the first 6 months on ART. After 3 
and 6 months on treatment, the mean BMI increase was, 
respectively, 0.95 and 1.51 kg/m
2; results similar to those 
found in other studies [11]. 
  The power of the study was not sufficient to investigate a 
detailed dose response effect of the BMI changes on 
mortality. As it is the first time such an analysis has been 
performed, we chose cut-off points to ensure enough patients 
in each group. Studying changes on a bigger cohort over a 
longer time could confirm these findings and improve 
knowledge of the implications of a wider range of 
Table 4.  Association Between Early Anthropometric Changes and Death, Univariate and Multivariate Analysis, Cox Regression 
 
   N  Deaths  HR (95% CI)  P – Value*  HR** (95% CI)  P – Value* 
BMI                
2 weeks (Missing 71)  <0.5 kg/m
2  306  44  2.18 (1.10; 4.34)  p = 0.002  2.47 (1.24; 4.93)  P=0.005 
  0.5 kg/m
2  140  10  1       
6 weeks (Missing 59)  <0.5 kg/m
2  180  17  2.80 (1.04; 7.61)  p = 0.028  3.41 (1.24; 9.39)  P=0.01 
  0.5 kg/m
2  166  5  1       
MUAC              
2 weeks (Missing 73)  <0.5 cm
  323  46  2.71 (1.16; 6.37)  p=0.009  2.78 (1.18; 6.53)  P= 0.008 
  0.5 cm  121  6  1      
6 Weeks (Missing 59)  <0.5 cm
  203  17  2.18 (0.81; 5.93)  p=0.10  2.34 (0.85; 6.39)  P=0.078 
  0.5 cm  143  5  1      
* Likelihood ratio test. 
** Adjusted for sex, age, baseline HIV stage, baseline BMI for BMI changes and baseline MUAC for MUAC changes. 
 
 
Fig. (3). Kaplan-Meier survival by Baseline BMI and BMI change after 2 weeks on ART. The table shows the number of individuals still 
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anthropometric changes over a long period of time on ART. 
The study only continued for one year, thus many of the 
patients had short follow-up times due to right censoring at 
the end of the study, not loss to follow-up. 
  Missing data for patients who came to the clinic were not 
missing at random and were strongly associated with death. 
Patients who are unable to stand cannot get their weight 
measured. Missing data on these patients is likely to have led 
to underestimation of the effects seen, as patients who are 
unable to stand are unlikely to have gained weight and 
probably had a poor prognosis. It is not clear why MUAC 
was also not measured in these patients. Measurement errors 
in the BMI and MUAC are also likely to have led to an 
underestimate in the associations seen as they are likely to 
have been random. We were unable to assess whether the 
predictive value of anthropometric changes was independent 
of changes in known predictors such as CD4 count and viral 
load. National guidelines allowed clinical staging as criteria 
sufficient for ART initiation in the absence of CD4 count 
and no CD4 testing was available at the hospital during the 
study. Knowing whether anthropometric changes were 
predictors independently of CD4 and viral load was not the 
purpose of the analysis, as the criteria are suggested for use 
in situations which rely on clinical judgement. 
  This study took place in conditions similar to routine 
HIV care in rural Malawi. Simple clinical tools to detect 
patients at higher risk of death just after ART initiation are 
much needed. We propose appropriate simple tools. It 
remains to be seen how much identifying those at particular 
risk can improve their prognosis. 
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